Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate

TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.

The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.